No Data
INNOCARE (09969.HK) repurchased 0.1 million shares at a cost of 0.599 million Hong Kong dollars on December 27.
Gelonghui, December 27, INNOCARE (09969.HK) announced that on December 27, it spent 0.599 million HKD to repurchase 0.1 million shares.
Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.
The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.
INNOCARE (09969.HK) spent 0.6315 million HKD to repurchase 0.106 million shares on December 24.
Glory Hong Kong reported on December 24 that INNOCARE (09969.HK) announced that on December 24, 2024, it spent 0.6315 million Hong Kong dollars to repurchase 0.106 million shares, with the repurchase price ranging from 5.86 to 6 Hong Kong dollars per share.
InnoCare Pharma Granted Waiver for Director Appointment
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
INNOCARE (09969.HK) spent 1.4194 million Hong Kong dollars to repurchase 0.24 million shares on December 23.
Gelonghui, December 24丨INNOCARE (09969.HK) announced that on December 23, 2024, it spent 1.4194 million Hong Kong dollars to repurchase 0.24 million shares, at a repurchase price of 5.86-5.94 Hong Kong dollars per share.
